Drug-Delivering Aptamers Target Leukemia Stem Cells for One-Two Knockout Punch ... including both accelerated or myeloid blast phases of the ... Tumor-Induced B Cell Changes Reveal Potential ...

After 72 hours, the aptamer alone had reduced the cancer cells in culture by 40%, demonstrating the aptamer's toxicity to the cancer, the researchers report. When the aptamers carried the leukemia ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers report. The aptamers -- short single ...

As with all products, the MHRA will keep its safety under close review. The Medicines and Healthcare products Regulatory ...

The diagnosis of early acute granulocytic leukemia was made. The patient was treated with transfusions alone. In June the bone marrow continued to show the same prominence of blast cells ...

Figure 1: MDS constitute a complex range of stem-cell diseases. The defining feature of AML is the presence of many blast cells in the bone marrow of affected individuals. Normal bone marrow might ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers at the University of Illinois Urbana ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening ... seen in this disease in a relatively immature (also termed 'blast') state. Science X Daily and the Weekly Email Newsletter ...

Get Instant Summarized Text (Gist) A novel combination therapy shows promise in treating acute myelogenous leukemia (AML) by overcoming the differentiation blockade in myeloid progenitor cells ...

Results showed that the antibodies neutralized AML and prolonged survival in four separate mouse models of leukemia. Notably, the antibodies effectively targeted leukemic stem cells in bone ...